Pancreatic cancer drugs put to the test in early trial
NCT ID NCT04005690
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early phase trial is testing several targeted drugs in people with pancreatic cancer to see how they affect tumor biology. Researchers will compare tumor samples taken before and after treatment to understand which drugs might work best. The goal is not to treat the cancer directly, but to gather information that could guide future, more effective trials. About 90 participants with various stages of pancreatic cancer are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab
What this could lead to
If successful, this study could help design better, more personalized treatments for pancreatic cancer by showing which drugs affect tumor biology.
What could go wrong
This is a very early, small study focused on measuring drug effects in tumors, not on curing or treating the disease. Many drugs tested in early trials do not lead to approved treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact